12:00 AM
 | 
Aug 06, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Avastin bevacizumab regulatory update

Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) said a U.K. primary care trust cluster revoked a September 2011 policy and said it will no longer reimburse for off-label use of Avastin bevacizumab to treat wet age-related macular degeneration (AMD). Novartis said the board of the...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >